Previous 10 | Next 10 |
John Paulson’s 13F portfolio value increased from $3.21B to $3.85B this quarter. Paulson & Company's largest three positions are Horizon Therapeutics, Bausch Health, and BrightSphere Investment Group. The stake in Barrick Gold was more than doubled during the quarter. ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March: Cowen and Company 41 st Annual Health Care Conference (Virtual) Date: Tuesday, Mar. 2, 2021 Presentation Time: 1:30 p.m. ET The...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2020 Q4 earnings call. For further details see: Horizon Therapeutics Public Limited Company 2020 Q4 - Results - Earnings Call Presentation
-- The company joins the global community in lighting up landmarks to recognize Rare Disease Day on Feb. 28 -- -- March kicks-off the company’s donation match through Uplifting Athletes’ Reps for Rare Diseases program to further research for new therapies -- ...
Shares of Horizon Therapeutics (NASDAQ: HZNP) were trading higher on Wednesday following the company's announcement of its fourth-quarter and full-year 2020 financial results. Horizon Therapeutics' stock closed the day's trading session up by 13.3%. During its fourth-quarter tha...
Image source: The Motley Fool. Horizon Therapeutics PLC (NASDAQ: HZNP) Q4 2020 Earnings Call Feb 24, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Horizon Therapeutics PLC (HZNP) Q4 2020 Earnings Call Transcript ...
Horizon Therapeutics Public Limited Company (HZNP) Q4 2020 Earnings Conference Call February 24, 2021 8:00 AM ET Company Participants Tina Ventura – Senior Vice President-Investor Relations Tim Walbert – Chairman, President and Chief Executive Officer Karin Rosen – Execut...
Horizon Therapeutics ([[HZNP]] +7.0%) Q4 results: Revenues: $745.3M (+105.0% Y/Y).Tepezza (teprotumumab-trbw) Q4 net sales of $343.7M.Orphan and Rheumatology Segment: Krystexxa: $128.9M (+16%); Ravicti: $70.2M (+3%); Procysbi: $47.3M (+16%); Actimmune: $35.7M (+2...
Horizon Therapeutics (HZNP): Q4 Non-GAAP EPS of $1.28 beats by $0.21; GAAP EPS of $0.82 beats by $0.31.Revenue of $745.3M (+105.0% Y/Y) beats by $51.91M.Full-Year 2021 Net Sales Guidance of $2.70 Billion to $2.80 Billion ($2.68B consensus), Representing 25 Percent Growth at the Midpoint; Full...
-- Record Fourth-Quarter 2020 Net Sales of $745.3 Million Increased 105 Percent; Fourth-Quarter 2020 GAAP Net Income of $190.6 Million; Adjusted EBITDA of $371.0 Million -- -- Record Full-Year 2020 Net Sales of $2.20 Billion Driven by 110 Percent Growth in the Orphan Segme...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...